{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T02:28:49Z","timestamp":1766888929992,"version":"build-2065373602"},"reference-count":148,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T00:00:00Z","timestamp":1593907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20170818100531426","JCYJ20180507181627057"],"award-info":[{"award-number":["JCYJ20170818100531426","JCYJ20180507181627057"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007567","name":"City University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671995"],"award-info":[{"award-number":["81671995"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.gendis.2020.07.001","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T12:24:53Z","timestamp":1594124693000},"page":"502-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pandemic COVID-19: Current status and challenges of antiviral therapies"],"prefix":"10.1016","volume":"7","author":[{"given":"Winglam","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Liang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gendis.2020.07.001_bib91","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"1","year":"2020","journal-title":"Nat Microb"},{"year":"2020","series-title":"COVID-19 Coronavirus Pandemic","key":"10.1016\/j.gendis.2020.07.001_bib136"},{"year":"2020","series-title":"Revisiting the Dangers of the Coronavirus in the Ophthalmology Practice","author":"Seah","key":"10.1016\/j.gendis.2020.07.001_bib105"},{"issue":"3","key":"10.1016\/j.gendis.2020.07.001_bib35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J Pharmaceut Anal"},{"issue":"11","key":"10.1016\/j.gendis.2020.07.001_bib102","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.gendis.2020.07.001_bib95","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol"},{"first-page":"70","year":"2020","series-title":"Coronavirus Disease 2019 (COVID-19): Situation Report","key":"10.1016\/j.gendis.2020.07.001_bib137"},{"year":"2020","series-title":"Coronavirus Disease 2019 Cases in the US","key":"10.1016\/j.gendis.2020.07.001_bib21"},{"issue":"10231","key":"10.1016\/j.gendis.2020.07.001_bib123","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","article-title":"COVID-19 and Italy: what next?","volume":"395","author":"Remuzzi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2020.07.001_bib15","first-page":"12","article-title":"Time to use the p-word? Coronavirus enter dangerous new phase","volume":"579","author":"Callaway","year":"2020","journal-title":"Nature"},{"year":"2020","series-title":"COVID-19 Drug Therapy \u2014 Potential Options","author":"Tim","key":"10.1016\/j.gendis.2020.07.001_bib120"},{"key":"10.1016\/j.gendis.2020.07.001_bib121","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.gendis.2020.07.001_bib146","doi-asserted-by":"crossref","first-page":"15092","DOI":"10.1038\/ncomms15092","article-title":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains","volume":"8","author":"Yuan","year":"2017","journal-title":"Nat Commun"},{"issue":"42","key":"10.1016\/j.gendis.2020.07.001_bib127","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1073\/pnas.1708727114","article-title":"Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion","volume":"114","author":"Walls","year":"2017","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"14","key":"10.1016\/j.gendis.2020.07.001_bib10","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1073\/pnas.0809524106","article-title":"Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites","volume":"106","author":"Belouzard","year":"2009","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"6483","key":"10.1016\/j.gendis.2020.07.001_bib134","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.gendis.2020.07.001_bib44","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1128\/JVI.01394-09","article-title":"Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission","volume":"84","author":"Graham","year":"2010","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/cr.2016.152","article-title":"Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding","volume":"27","author":"Gui","year":"2017","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.gendis.2020.07.001_bib128","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.gendis.2020.07.001_bib96","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virol.2006.11.027","article-title":"The intracellular sites of early replication and budding of SARS-coronavirus","volume":"361","author":"Stertz","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.gendis.2020.07.001_bib145","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [published online ahead of print, 2020 Mar 9]","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"year":"2020","series-title":"Patient-derived Mutations Impact Pathogenicity of SARS-CoV-2","author":"Yao","key":"10.1016\/j.gendis.2020.07.001_bib144"},{"year":"2020","series-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","author":"Wu","key":"10.1016\/j.gendis.2020.07.001_bib140"},{"issue":"5","key":"10.1016\/j.gendis.2020.07.001_bib70","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV","volume":"21","author":"Liu","year":"2020","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.gendis.2020.07.001_bib148","article-title":"Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov","author":"Zhao","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.gendis.2020.07.001_bib38","series-title":"Coronaviruses","first-page":"1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","author":"Fehr","year":"2015"},{"issue":"10224","key":"10.1016\/j.gendis.2020.07.001_bib72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2020.07.001_bib53","article-title":"The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells","author":"Hoffmann","year":"20200131","journal-title":"bioRxiv"},{"key":"10.1016\/j.gendis.2020.07.001_bib142","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Res Med"},{"issue":"10223","key":"10.1016\/j.gendis.2020.07.001_bib56","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2020.07.001_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile","volume":"104","author":"Mahallawi","year":"2018","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.gendis.2020.07.001_bib124","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMc2004973","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1","volume":"382","author":"van Doremalen","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.gendis.2020.07.001_bib109","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.humpath.2004.11.006","article-title":"Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan","volume":"36","author":"Shieh","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1016\/j.gendis.2020.07.001_bib23","first-page":"529","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"vol. 39","author":"Channappanavar","year":"2017"},{"issue":"10223","key":"10.1016\/j.gendis.2020.07.001_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2020.07.001_bib34","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","author":"Diao","year":"2020","journal-title":"Medrxiv"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep25359","article-title":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity","volume":"6","author":"Min","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jmv.20255","article-title":"An interferon-\u03b3-related cytokine storm in SARS patients","volume":"75","author":"Huang","year":"2005","journal-title":"J Med Virol"},{"issue":"20","key":"10.1016\/j.gendis.2020.07.001_bib66","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa030685","article-title":"A major outbreak of severe acute respiratory syndrome in Hong Kong","volume":"348","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.gendis.2020.07.001_bib89","first-page":"4956","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics","volume":"22","author":"Nassar","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib82","first-page":"2012","article-title":"Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV","volume":"24","author":"Meo","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"9","key":"10.1016\/j.gendis.2020.07.001_bib8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1473-3099(13)70204-4","article-title":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study","volume":"13","author":"Assiri","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.gendis.2020.07.001_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa410","article-title":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 [published online ahead of print, 2020 Apr 9]","author":"Chu","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.gendis.2020.07.001_bib46","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.gendis.2020.07.001_bib150","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Preliminary Report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"6498","key":"10.1016\/j.gendis.2020.07.001_bib153","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural Basis for Inhibition of the RNA-dependent RNA Polymerase from SARS-CoV-2 by Remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.gendis.2020.07.001_bib2","series-title":"Current Knowledge about the Antivirals Remdesivir (GS-5734) and GS-441524 as Therapeutic Options for Coronaviruses","first-page":"100128","author":"Amirian","year":"2020"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.gendis.2020.07.001_bib129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"7594","key":"10.1016\/j.gendis.2020.07.001_bib133","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV nsp 12 polymerase bound to nsp 7 and nsp 8 co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat Commun"},{"year":"2020","series-title":"Early Report on Remdesivir: Is There a Benefit for Severe COVID-19?","author":"Bender","key":"10.1016\/j.gendis.2020.07.001_bib11"},{"year":"2020","series-title":"Gilead's Remdesivir Enters China Phase III Trial to Fight Coronavirus","author":"Mak","key":"10.1016\/j.gendis.2020.07.001_bib79"},{"key":"10.1016\/j.gendis.2020.07.001_bib45","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.gendis.2020.07.001_bib18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"12","key":"10.1016\/j.gendis.2020.07.001_bib112","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.0306446101","article-title":"Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry","volume":"101","author":"Simmons","year":"2004","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"33","key":"10.1016\/j.gendis.2020.07.001_bib111","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.virol.2011.02.020","article-title":"Different host cell proteases activate the SARS-coronavirus spike-protein for cell\u2013cell and virus\u2013cell fusion","volume":"413","author":"Simmons","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.gendis.2020.07.001_bib33","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib63","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2007.10.011","article-title":"Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK","volume":"77","author":"Kono","year":"2008","journal-title":"Antivir Res"},{"issue":"7","key":"10.1016\/j.gendis.2020.07.001_bib149","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"75","author":"Zhou","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","article-title":"Clinical pharmacokinetics and metabolism of chloroquine","volume":"31","author":"Ducharme","year":"1996","journal-title":"Clin Pharmacokinet"},{"year":"2020","series-title":"Chloroquine: Is a 70-Year-Old Treatment for Malaria the Key to Beating Coronavirus? the Telegraph","author":"Gulland","key":"10.1016\/j.gendis.2020.07.001_bib49"},{"year":"2020","series-title":"Will an Old Malaria Drug Help Fight the Coronavirus? France 24","author":"S\u00e9bastian","key":"10.1016\/j.gendis.2020.07.001_bib106"},{"year":"2020","series-title":"Expanded Access Remdesivir (RDV;GS-5734)","key":"10.1016\/j.gendis.2020.07.001_bib28"},{"year":"2020","series-title":"The Vietnam Chloroquine Treatment on COVID-19 (VICO)","key":"10.1016\/j.gendis.2020.07.001_bib29"},{"key":"10.1016\/j.gendis.2020.07.001_bib41","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","author":"Gao","year":"2020","journal-title":"Bioscience trends"},{"key":"10.1016\/j.gendis.2020.07.001_bib30","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.gendis.2020.07.001_bib14","series-title":"Hydroxychloroquine and Chloroquine Retinopathy","first-page":"35","article-title":"Pharmacology of chloroquine and hydroxychloroquine","author":"Browning","year":"2014"},{"issue":"5","key":"10.1016\/j.gendis.2020.07.001_bib98","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"issue":"9","key":"10.1016\/j.gendis.2020.07.001_bib13","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Biot","year":"2006","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-019-0132-8","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in\u00a0vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell discovery"},{"key":"10.1016\/j.gendis.2020.07.001_bib42","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib103","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1183\/09031936.00102014","article-title":"Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells","volume":"45","author":"Sch\u00f6gler","year":"2015","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.gendis.2020.07.001_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01152-17","article-title":"Azithromycin shows anti-Zika virus activity in human glial cells","volume":"61","author":"Iannetta","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.gendis.2020.07.001_bib76","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect Dis"},{"year":"2020","series-title":"Hydroxychloroquine or Chloroquine with or without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis","author":"Mandeep","key":"10.1016\/j.gendis.2020.07.001_bib151"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/102490790701400110","article-title":"A case of fatal hydroxychloroquine overdose","volume":"14","author":"Fung","year":"2007","journal-title":"Hong Kong J Emerg Med"},{"issue":"5","key":"10.1016\/j.gendis.2020.07.001_bib87","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/RHU.0b013e31829d5e50","article-title":"Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus","volume":"19","author":"Morgan","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.gendis.2020.07.001_bib9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/OPTH.S8372","article-title":"Ocular onchocerciasis: current management and future prospects","volume":"5","author":"Babalola","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib116","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jmedent\/45.1.75","article-title":"A new ivermectin formulation topically kills permethrin-resistant human head lice (Anoplura: pediculidae)","volume":"45","author":"Strycharz","year":"2008","journal-title":"J Med Entomol"},{"issue":"3","key":"10.1016\/j.gendis.2020.07.001_bib126","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.gendis.2020.07.001_bib119","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.antiviral.2013.06.002","article-title":"Nuclear localization of dengue virus (DENV) 1\u20134 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin","volume":"99","author":"Tay","year":"2013","journal-title":"Antivir Res"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib47","first-page":"1","article-title":"Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import","volume":"6","author":"G\u00f6tz","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.gendis.2020.07.001_bib143","series-title":"The Broad Spectrum Antiviral Ivermectin Targets the Host Nuclear Transport Importin \u03b1\/\u03b21 Heterodimer","first-page":"104760","author":"Yang","year":"2020"},{"issue":"17","key":"10.1016\/j.gendis.2020.07.001_bib100","doi-asserted-by":"crossref","first-page":"11507","DOI":"10.1128\/JVI.79.17.11507-11512.2005","article-title":"Intracellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein: absence of nucleolar accumulation during infection and after expression as a recombinant protein in Vero cells","volume":"79","author":"Rowland","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.gendis.2020.07.001_bib16","series-title":"The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in\u00a0Vitro","first-page":"104787","author":"Caly","year":"2020"},{"key":"10.1016\/j.gendis.2020.07.001_bib84","article-title":"Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view","author":"Momekov","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.gendis.2020.07.001_bib17","series-title":"Ivermectin and Abamectin","first-page":"245","article-title":"Use of ivermectin in dogs and cats","author":"Campbell","year":"1989"},{"issue":"6","key":"10.1016\/j.gendis.2020.07.001_bib94","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jaad.2020.04.017","article-title":"Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and\/or treatment?","volume":"82","author":"Patr\u00ec","year":"2020","journal-title":"J Am Acad Dermatol"},{"year":"2020","series-title":"Gates Foundation Funded French Research Group Commences Ivermectin Clinical Trial Targeting COVID-19","author":"TriaSiteNews","key":"10.1016\/j.gendis.2020.07.001_bib122"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib58","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.gendis.2020.07.001_bib62","first-page":"489","article-title":"Successful treatment of avian influenza with convalescent plasma","volume":"12","author":"Kong","year":"2006","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.gendis.2020.07.001_bib141","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2015.10.009","article-title":"Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma","volume":"41","author":"Wu","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib78","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.gendis.2020.07.001_bib101","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jinf.2016.11.009","article-title":"Evaluation of convalescent whole blood for treating Ebola virus disease in freetown, Sierra Leone","volume":"74","author":"Sahr","year":"2017","journal-title":"J Infect"},{"year":"2014","key":"10.1016\/j.gendis.2020.07.001_bib138"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Arabi","year":"2015","journal-title":"SpringerPlus"},{"issue":"7","key":"10.1016\/j.gendis.2020.07.001_bib61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.gendis.2020.07.001_bib19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc070348","article-title":"Disappearance of antibodies to SARS-associated coronavirus after recovery","volume":"357","author":"Cao","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib147","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jmv.20431","article-title":"A serological survey on neutralizing antibody titer of SARS convalescent sera","volume":"77","author":"Zhang","year":"2005","journal-title":"J Med Virol"},{"issue":"9","key":"10.1016\/j.gendis.2020.07.001_bib5","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"16","key":"10.1016\/j.gendis.2020.07.001_bib108","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"year":"2020","series-title":"The Feasibility of Convalescent Plasma Therapy in Severe COVID-19 Patients: A Pilot Study","author":"Duan","key":"10.1016\/j.gendis.2020.07.001_bib36"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"issue":"6288","key":"10.1016\/j.gendis.2020.07.001_bib71","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1\u2013infected cells by broadly neutralizing antibodies against HIV-1 in\u00a0vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.gendis.2020.07.001_bib73","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"issue":"9956","key":"10.1016\/j.gendis.2020.07.001_bib52","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(14)61034-5","article-title":"Hepatitis E virus in blood components: a prevalence and transmission study in southeast England","volume":"384","author":"Hewitt","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.gendis.2020.07.001_bib86","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S2213-2600(15)00180-0","article-title":"Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain","volume":"3","author":"Mora-Rillo","year":"2015","journal-title":"Lancet Resp Med"},{"issue":"5","key":"10.1016\/j.gendis.2020.07.001_bib31","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1097\/01.CCM.0000214293.72918.D8","article-title":"Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies","volume":"34","author":"Curtis","year":"2006","journal-title":"Crit Care Med"},{"year":"2020","series-title":"Convalescent Plasma Therapy for Covid-19: State of the Art","author":"Focosi","key":"10.1016\/j.gendis.2020.07.001_bib39"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.2009.07840.x","article-title":"Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill","volume":"147","author":"Benson","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.gendis.2020.07.001_bib50","series-title":"Dengue Antibody-Dependent Enhancement: Knowns and Unknowns","first-page":"249","author":"Halstead","year":"2015"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"Wang","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"year":"2020","series-title":"Rajeev Venkayya, President, Global Vaccine Business Unit on the Latest on the Coronavirus and Takeda","author":"Takeda","key":"10.1016\/j.gendis.2020.07.001_bib117"},{"year":"2020","series-title":"Kamada to Attempt Coronavirus Treatment","author":"Weinreb","key":"10.1016\/j.gendis.2020.07.001_bib132"},{"issue":"8","key":"10.1016\/j.gendis.2020.07.001_bib51","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41590-018-0163-6","article-title":"Natural killer cell specificity for viral infections","volume":"19","author":"Hammer","year":"2018","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.gendis.2020.07.001_bib64","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib118","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/jvi.71.1.267-275.1997","article-title":"Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells","volume":"71","author":"Tay","year":"1997","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.gendis.2020.07.001_bib93","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/1521-4141(2002010)32:10<2881::AID-IMMU2881>3.0.CO;2-K","article-title":"Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control","volume":"32","author":"Pardo","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.gendis.2020.07.001_bib131","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib113","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK cell cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.gendis.2020.07.001_bib65","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1086\/512860","article-title":"Antibody-dependent cellular cytotoxity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication","volume":"195","author":"Laoprasopwattana","year":"2007","journal-title":"J Infect Dis"},{"issue":"5571","key":"10.1016\/j.gendis.2020.07.001_bib6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1070884","article-title":"Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors","volume":"296","author":"Arase","year":"2002","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib99","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.4049\/jimmunol.138.4.1064","article-title":"Sera from HTLV-III\/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III\/LAV-infected T cells","volume":"138","author":"Rook","year":"1987","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.gendis.2020.07.001_bib90","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.cytogfr.2004.03.009","article-title":"The role of IL-12, IL-23 and IFN-\u03b3 in immunity to viruses","volume":"15","author":"Novelli","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib67","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/eji.201040304","article-title":"Here today\u2013not gone tomorrow: roles for activating receptors in sustaining NK cells during viral infections","volume":"40","author":"Lee","year":"2010","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.gendis.2020.07.001_bib104","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"3","key":"10.1016\/j.gendis.2020.07.001_bib92","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4049\/jimmunol.156.3.1138","article-title":"An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections","volume":"156","author":"Orange","year":"1996","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.gendis.2020.07.001_bib85","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1128\/JVI.72.6.4825-4831.1998","article-title":"Role of interleukin-12 in primary influenza virus infection","volume":"72","author":"Monteiro","year":"1998","journal-title":"J Virol"},{"year":"2020","series-title":"Natural Killer Cell (CYNK-001) Infusions in Adults with COVID-19 (CYNK-001-COVID-19) (CYNK001COVID)","key":"10.1016\/j.gendis.2020.07.001_bib152"},{"year":"2019","series-title":"Natural Killer Cell Therapy: A Look inside a \u2018Living Drug in a Bottle\u2019","author":"Amorosi","key":"10.1016\/j.gendis.2020.07.001_bib3"},{"year":"2020","series-title":"Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection","author":"GlobeNewswire","key":"10.1016\/j.gendis.2020.07.001_bib43"},{"year":"2013","series-title":"Research as a Part of Public Health Emergency Response","author":"Lurie","key":"10.1016\/j.gendis.2020.07.001_bib74"},{"issue":"1","key":"10.1016\/j.gendis.2020.07.001_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archderm.141.1.76","article-title":"Clinical trial registration: a statement from the international committee of medical journal","volume":"141","author":"DeAngelis","year":"2005","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.gendis.2020.07.001_bib75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing Clinical Trials for the Management of the COVID-19 Pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol Sci."},{"key":"10.1016\/j.gendis.2020.07.001_bib55","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gendis.2020.07.001_bib97","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent discovery and development of inhibitors targeting coronaviruses","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.gendis.2020.07.001_bib88","first-page":"1","article-title":"Chronology of COVID-19 cases on the Diamond Princess cruise ship and ethical considerations: a report from Japan","author":"Nakazawa","year":"2020","journal-title":"Disaster Med Public Health Prep"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304220300830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304220300830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:26:07Z","timestamp":1762449967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304220300830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":148,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2352304220300830"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2020.07.001","relation":{},"ISSN":["2352-3042"],"issn-type":[{"type":"print","value":"2352-3042"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pandemic COVID-19: Current status and challenges of antiviral therapies","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2020.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chongqing Medical University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}